Bioaffinity Technologies, INC DEF 14A proxy statements

BioAffinity Technologies, Inc. calls for its Annual Meeting to approve a reverse stock split, significant equity plan expansion, and authorization for future dilutive capital raises.

BioAffinity Technologies, Inc. issued a supplement to its proxy statement to correct a clerical error in the number of outstanding common shares for its upcoming Special Meeting.

bioAffinity Technologies calls a Special Meeting to approve significant share issuances, anti-dilution adjustments, and a large equity plan increase, signaling substantial future dilution.

bioAffinity Technologies, Inc. has filed a Definitive Proxy Statement (Schedule 14A) with the U.S. Securities and Exchange Commission.

bioAffinity Technologies, a developer of noninvasive lung cancer diagnostics, is calling an Annual Meeting on July 25, 2025, to seek shareholder approval for a reverse stock split, a substantial increase in authorized shares, and the issuance of millions of shares from warrant exercises, primarily to address Nasdaq listing compliance and facilitate future capital raising.

bioAffinity Technologies is holding a special meeting to seek stockholder approval for the issuance of shares related to warrants from a recent offering.

bioAffinity Technologies is holding a special meeting to seek stockholder approval for the issuance of shares upon the exercise of warrants, aiming to secure up to $2.7 million in gross proceeds to fund operations.

bioAffinity Technologies has filed a definitive proxy statement with the SEC.

bioAffinity Technologies is holding its annual stockholder meeting on June 4, 2024, to vote on key proposals including director elections, an incentive compensation plan, and an increase in authorized shares.